证券时报·数据宝统计，截至8月26日收盘，沪深两市共504只个股连续5日或5日以上主力资金净流出。 从净流出持续时间来看，宏创控股连续23日主力资金净流出，排名第一；欣锐科技连续21日主力资金净 流出，位列第二。从主力资金净流出总规模来看，内蒙一机主力资金净流出金额最大，连续9天累计净 流出43.62亿元，工业富联紧随其后，5天累计净流出43.14亿元。从主力资金净流出占成交金额的比例来 看，ST德豪占比排名居首，该股近5日下跌11.94%。（数据宝） | 证券代 | 证券简 | 主力资金净流出 | 主力资金净流出金额 | 主力资金净流出比例 | 累计涨跌幅 | | --- | --- | --- | --- | --- | --- | | 码 | 称 | 天数 | （亿元） | （%） | （%） | | 600967 | 内蒙一 机 | 9 | 43.62 | 11.48 | -12.09 | | 601138 | 工业富 联 | 5 | 43.14 | 7.46 | -7.01 | | 603259 | 药明康 德 | 8 | 41.13 | 7.36 | -1.91 | | 600580 | 卧龙电 ...

Group 1 - The CRO concept sector experienced a decline of 2.00%, ranking among the top declines in concept sectors, with notable declines in companies such as Yangguang Nuohuo, Meihao Medical, and Haitai Biological [1][2] - Among the 49 stocks in the CRO sector, 13 stocks saw price increases, with Tai Long Pharmaceutical, Puni Testing, and ST Weiming leading the gains at 5.39%, 2.84%, and 1.10% respectively [1][2] - The CRO sector faced a net outflow of 3.065 billion yuan in capital, with Han Yu Pharmaceutical experiencing the largest outflow of 766.13 million yuan, followed by WuXi AppTec and Kanglong Chemical with outflows of 706.94 million yuan and 169.89 million yuan respectively [2][4] Group 2 - The top gainers in the CRO sector included Lianhua Technology, Meinuo Pharmaceutical, and Tai Long Pharmaceutical, with net inflows of 17.76 million yuan, 17.24 million yuan, and 11.20 million yuan respectively [2][4] - The CRO concept sector's performance was contrasted with other sectors, such as the Tonghuashun Fruit Index which increased by 3.11%, and the chicken farming sector which rose by 2.87% [2][3] - The trading volume and turnover rates varied significantly among the stocks, with Han Yu Pharmaceutical showing a turnover rate of 16.12% alongside a price drop of 5.94% [3][4]

Group 1 - The innovative drug concept sector declined by 1.25%, ranking among the top declines in concept sectors, with notable declines in companies such as Yuandong Biological, Sunshine Nuohong, and Guangshengtang [1][2] - Among the innovative drug concept stocks, 64 stocks experienced price increases, with ST Xiangxue, Wanbangde, and Haixiang Pharmaceutical leading the gains at 12.45%, 9.97%, and 6.13% respectively [1][2] Group 2 - The innovative drug concept sector saw a net outflow of 6.686 billion yuan, with 160 stocks experiencing net outflows, and 17 stocks having outflows exceeding 100 million yuan [2] - The stock with the highest net outflow was Hanyu Pharmaceutical, with a net outflow of 766.13 million yuan, followed by WuXi AppTec, Sile Medical, and Guangshengtang with net outflows of 706.94 million yuan, 408.68 million yuan, and 360.09 million yuan respectively [2][3] Group 3 - The top gainers in the innovative drug concept sector included Wanbangde, Anke Biological, and Borui Pharmaceutical, with net inflows of 111 million yuan, 80.22 million yuan, and 75.74 million yuan respectively [2][10] - The innovative drug concept sector's performance was contrasted by the top gainers in other sectors, such as the Tonghuashun Fruit Index, which increased by 3.11% [2]

据香港交易所披露，花旗集团对无锡药明康德新药开发股份有限公司 - H股的多头持仓比例于2025年8 月20日从4.71%增至5.12%。摩根大通（JPMorgan）对无锡药明康德新药开发股份有限公司 - H股的多头 持仓比例于2025年8月21日从5.87%增至6.01%。 ...

格隆汇8月26日丨药明康德(02359.HK)发布公告，2025年8月26日耗资4280.27万元人民币回购43.98万股 A股，回购价格每股96.68-98.61元。 ...

智通财经APP讯，药明康德(02359)公布，2025年8月26日耗资约4280.27万元回购43.98万股A股股份。 ...

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 無錫藥明康德新藥開發股份有限公司 呈交日期： 2025年8月26日 第 2 頁 共 13 頁 v 1.3.0 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 A | | 於香港聯交所上市 | 否 | | | 證券代號 (如上市) | | 說明 | 於上海證券交易所上市 | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | 庫存股份變動 | | | | | 事件 | 已發行股份（不包括庫存 ...

中信建投（601066）证券股份有限公司研究员贺菊颖、刘若飞、赖俊勇、汤然发布研报《药明康德：在 手订单保持强劲 小分子D&M及TIDES持续发力》称，维持买入评级。 中国经济网北京8月26日讯药明康德（603259）(603259.SH)今日收报96.80元，跌幅3.18%。 药明康德今年7月30日股价盘中达到102.49元，创年内新高，当日共有7家券商发布研报，其中5家维 持"买入"评级。 华西证券（002926）股份有限公司研究员崔文亮、徐顺利发布研报《药明康德：业绩延续快速增长 在 手订单维持高速增长》称，维持"买入"评级。 浦银国际证券有限公司研究员阳景、胡泽宇发布研报《药明康德：2Q25业绩显著超预期 上调全年指 引》称，维持"买入"评级。 西部证券（002673）股份有限公司研究员李梦园、徐子悦发布研报《药明康德2025年中报点评：中报业 绩超预期 下半年利润率有望进一步提升》称，维持"买入"评级。 光大证券股份有限公司研究员王明瑞、叶思奥发布研报《药明康德：毛利率改善明显 TIDES业务增长 强劲》称，维持"买入"评级。 招商证券股份有限公司研究员梁广楷、许菲菲、肖笑园发布研报《药明康德：持续 ...

Core Insights - The Chinese biopharmaceutical industry is experiencing a surge in performance, with 69.23% of 39 innovative drug companies reporting positive net profit growth in their semi-annual reports [1] - Six companies reported over 100% year-on-year growth in net profit, indicating strong development momentum in the sector [1] Company Performance - **Kexing Pharmaceutical** achieved the highest net profit growth at 576.45%, totaling 0.80 billion yuan, focusing on antiviral, oncology, and immunology treatments [1] - **Sanno Bio** reported a 308.29% increase in net profit, reaching 0.89 billion yuan, driven by significant growth in raw material drug sales [2][3] - **Jinkai Biotechnology** saw a 123.61% increase in net profit, providing custom development services for small molecule drugs [3] - **Wuxi AppTec** and **Hengrui Medicine** also ranked among the top three companies by revenue, with 207.99 billion yuan and 157.61 billion yuan respectively [4] Industry Trends - The industry is transitioning from an "investment phase" to a "harvest phase," indicating a recovery in profitability and a moderate expansion stage [4] - Recent policy measures from the National Healthcare Security Administration aim to support high-quality development in innovative drug research and market application [4] - Analysts predict that the innovative drug sector will continue to thrive, driven by efficiency and cost advantages in drug development [5]

据香港交易所披露，贝莱德对无锡药明康德新药开发股份有限公司 - H股的多头持仓比例于2025年8月 20日从5.35%降至4.84%。 ...